FOI 9631 – Q1

How many new patients were treated for any condition by the Trust's Dermatology Department in the latest 3-month period of April, May and June 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Psoriasis.

Please can you define a "new patient" as a patient who is receiving any of the treatments listed below for the first time. If a patient received any of the below treatments in 2024 or previous years, they can be classed as a new patient for this period.

IS notes: *Where volumes are 5 or less, these have been replaced with '<=5' so they are not patient identifiable*

	Total Dermatology Department	Psoriasis
Adalimumab [Humira]	0	0
Adalimumab [All Biosimilars]	<=5	0
Apremilast [Otezla]	0	0
Apremilast [Generic]	0	0
Etanercept [Enbrel]	0	0
Etanercept [All Biosimilars]	0	0
Infliximab [Remicade]	0	0
Infliximab [All Biosimilars]	0	0
Ustekinumab [Stelara]	0	0
Ustekinumab [All Biosimilars]	0	0
Bimekizumab [Bimzelx]	<=5	<=5
Brodalumab [Kyntheum]	0	0
Certolizumab [Cimzia]	0	0
Deucravacitinib [Sotyktu]	0	0
Dimethyl Fumarate [Skilarence]	0	0
Guselkumab [Tremfya]	0	0
Ixekizumab [Taltz]	0	0
Risankizumab [Skyrizi]	0	0
Secukinumab [Cosentyx]	0	0

Spesolimab [Spevigo]	0	0
Tildrakizumab [illumetri]	0	0